Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 106.0
(-2.0%)
INR 106.0
(-2.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 6.19 Billion INR | -6.16% |
| 2022 | 4.4 Billion INR | 7.53% |
| 2021 | 4.09 Billion INR | 9.2% |
| 2020 | 3.75 Billion INR | 21.0% |
| 2019 | 3.09 Billion INR | 9.65% |
| 2018 | 2.82 Billion INR | -2.79% |
| 2017 | 2.9 Billion INR | 18.55% |
| 2016 | 2.45 Billion INR | -0.96% |
| 2015 | 2.47 Billion INR | 26.63% |
| 2014 | 1.95 Billion INR | 24.85% |
| 2013 | 1.56 Billion INR | -11.73% |
| 2012 | 1.77 Billion INR | -30.59% |
| 2011 | 2.55 Billion INR | -3.22% |
| 2010 | 2.64 Billion INR | 49.08% |
| 2009 | 1.77 Billion INR | 7.6% |
| 2008 | 1.64 Billion INR | 31.72% |
| 2007 | 1.25 Billion INR | 31.16% |
| 2006 | 953.4 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -4.81 Million INR | -101.7% |
| 2023 Q1 | 1.48 Billion INR | 384.57% |
| 2023 FY | 4.13 Billion INR | -6.16% |
| 2023 Q4 | 282.74 Million INR | -78.59% |
| 2023 Q3 | 1.32 Billion INR | -9.07% |
| 2023 Q2 | 1.45 Billion INR | -1.9% |
| 2022 Q1 | 1.36 Billion INR | 278.13% |
| 2022 FY | 4.4 Billion INR | 7.53% |
| 2022 Q4 | 305.58 Million INR | -76.51% |
| 2022 Q3 | 1.3 Billion INR | -9.41% |
| 2022 Q2 | 1.43 Billion INR | 5.46% |
| 2021 Q1 | 1.22 Billion INR | 384.51% |
| 2021 Q4 | 360.12 Million INR | -73.51% |
| 2021 Q3 | 1.35 Billion INR | 3.94% |
| 2021 Q2 | 1.3 Billion INR | 6.75% |
| 2021 FY | 4.09 Billion INR | 9.2% |
| 2020 FY | 3.75 Billion INR | 21.0% |
| 2020 Q2 | 1.22 Billion INR | 22.58% |
| 2020 Q3 | 1.13 Billion INR | -7.14% |
| 2020 Q4 | 252.93 Million INR | -77.74% |
| 2020 Q1 | 998.18 Million INR | 179.09% |
| 2019 Q4 | 357.65 Million INR | -64.45% |
| 2019 FY | 3.09 Billion INR | 9.65% |
| 2019 Q3 | 1 Billion INR | 14.58% |
| 2019 Q2 | 878.03 Million INR | -9.02% |
| 2019 Q1 | 965.11 Million INR | 545.61% |
| 2018 Q2 | 866.45 Million INR | -10.11% |
| 2018 FY | 2.82 Billion INR | -2.79% |
| 2018 Q4 | 149.48 Million INR | -83.49% |
| 2018 Q1 | 963.91 Million INR | 0.0% |
| 2018 Q3 | 905.53 Million INR | 4.51% |
| 2017 FY | 2.9 Billion INR | 18.55% |
| 2016 FY | 2.45 Billion INR | -0.96% |
| 2015 FY | 2.47 Billion INR | 26.63% |
| 2014 FY | 1.95 Billion INR | 24.85% |
| 2013 FY | 1.56 Billion INR | -11.73% |
| 2012 Q2 | 533.32 Million INR | 144.33% |
| 2012 FY | 1.77 Billion INR | -30.59% |
| 2012 Q3 | 747.44 Million INR | 40.15% |
| 2012 Q1 | 218.27 Million INR | 0.0% |
| 2012 Q4 | 285.82 Million INR | -61.76% |
| 2011 FY | 2.55 Billion INR | -3.22% |
| 2010 FY | 2.64 Billion INR | 49.08% |
| 2009 FY | 1.77 Billion INR | 7.6% |
| 2008 FY | 1.64 Billion INR | 31.72% |
| 2007 FY | 1.25 Billion INR | 31.16% |
| 2006 FY | 953.4 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 70.593% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -297.959% |
| Sigachi Industries Limited | 2 Billion INR | -209.365% |
| Bal Pharma Limited | 770.19 Million INR | -704.259% |
| Medico Remedies Limited | 262.14 Million INR | -2262.961% |
| Lasa Supergenerics Limited | 121.02 Million INR | -5018.037% |
| Venus Remedies Limited | 2.18 Billion INR | -183.808% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 1128.27% |
| Alpa Laboratories Limited | 188.89 Million INR | -3179.261% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -108.42% |
| Shilpa Medicare Limited | 3.54 Billion INR | -74.643% |
| Aarti Drugs Limited | 8.31 Billion INR | 25.515% |
| Lupin Limited | 123.71 Billion INR | 94.993% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 95.995% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 95.053% |
| Windlas Biotech Limited | 1.33 Billion INR | -362.68% |
| Suven Life Sciences Limited | -200.79 Million INR | 3184.887% |
| Eris Lifesciences Limited | 10.42 Billion INR | 40.592% |
| Valiant Laboratories Limited | -60.66 Million INR | 10310.932% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 72.712% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -619.271% |
| Ipca Laboratories Limited | 29.8 Billion INR | 79.22% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -67.622% |
| Achyut Healthcare Limited | 4.86 Million INR | -127329.747% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 97.604% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -320.868% |
| RPG Life Sciences Limited | 2.48 Billion INR | -149.471% |
| Mankind Pharma Limited | 44.52 Billion INR | 86.087% |
| Laurus Labs Limited | 24.62 Billion INR | 74.84% |
| Piramal Pharma Limited | 24.47 Billion INR | 74.687% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -557.297% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 86.752% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 76.87% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 91.067% |
| Unichem Laboratories Limited | 4.86 Billion INR | -27.327% |
| Sequent Scientific Limited | 2.97 Billion INR | -107.953% |
| Novartis India Limited | 1.32 Billion INR | -366.829% |
| Wanbury Limited | 1.73 Billion INR | -257.922% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -50.229% |
| Wockhardt Limited | 16.24 Billion INR | 61.857% |
| Themis Medicare Limited | 1.5 Billion INR | -311.885% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -849.196% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 68.465% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 50.178% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 96.214% |
| Divi's Laboratories Limited | 32.44 Billion INR | 80.905% |
| NATCO Pharma Limited | 25.73 Billion INR | 75.931% |
| Gufic Biosciences Limited | 4.16 Billion INR | -48.628% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -35.224% |
| Ind-Swift Limited | 2.17 Billion INR | -185.122% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -7.143% |
| FDC Limited | 8.33 Billion INR | 25.68% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -3114.059% |
| Granules India Limited | 16.79 Billion INR | 63.127% |
| Medicamen Biotech Limited | 495.49 Million INR | -1150.136% |
| Alkem Laboratories Limited | 52.29 Billion INR | 88.155% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 0.455% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -42386.197% |
| Brooks Laboratories Limited | 65.62 Million INR | -9339.744% |
| Megasoft Limited | 342.07 Million INR | -1710.84% |
| ZIM Laboratories Limited | 1.26 Billion INR | -388.943% |
| Strides Pharma Science Limited | 14.38 Billion INR | 56.948% |
| Neuland Laboratories Limited | 8.24 Billion INR | 24.897% |
| Morepen Laboratories Limited | 6.16 Billion INR | -0.537% |
| Hikal Limited | 3.14 Billion INR | -97.079% |
| Indoco Remedies Limited | 6.04 Billion INR | -2.533% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -6.225% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -898.322% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -780.375% |
| Hester Biosciences Limited | 1.27 Billion INR | -386.347% |